 Is a semi-virtual R&D biotech SME based in Bellshill,
Glasgow.
 Has developed a lead compound, LMS-611, which is a mimetic of a natural lamellar body.
 Is developing new medical devices and pharmacological products based on LMS-611.
 Has extensive research links with the NHS and academia, including clinical studies, research programs and PhD studentships, principally with
Scottish institutions.

Lamellar Biomedical’s mission is to research, develop and commercialise novel healthcare products based on the mimicry or modification of the lamellar body secretory system.

 Maintain the properties of mucosal tissues e.g. surface tension, moisture loss and lubrication.
 Manage the interface between tissues and the external environment as in the mouth and lungs.
 Have biophysical not pharmacological properties.
 Are NOT alveolar surfactant in form, location or function.

Lamellar bodies in upper airways
EM of a human lamellar body with tightly packed concentric rings
Lamellar’s mimetic lamellar body (LMS-611) with similar 3D microstructure & properties.
Confocal micrograph of LMS-611

1. Radiotherapy Induced Xerostomia
(Dry mouth)
3. Cystic Fibrosis
2. Dry Eye Disease

• Clinic: Beatson West of Scotland Cancer Clinic.
• Facilities: Phase 1 Cancer CTU.
• Staff: Dr Claire Paterson, Maureen Thompson and Barry Caldwell
• Clinic: Glasgow Caledonian University Vision
Sciences.
• Facilities: Specialist regional ophthalmology centre and GGCHB Phase 1 unit.
• Staff: Drs Iain Pearce, Nail Strang & Louise
Madden.
• Clinics: UK CF specialist centre: West of
Scotland CF Unit.
• Facilities: Bespoke CF clinic with Phase 1 capabilities.
• Staff: Drs Bicknell, McGregor and McCartney
(West of Scotland).
West of Scotland CF Unit Logo

• Globally, 685,000 new cases of Head and Neck Cancer (HNC) every year.
• ~80% of HNC cases develop Radiotherapy -Induced Xerostomia (RIX) .
• RIX is the “most significant long-term complication of radiotherapy in
the head and neck region”
• DED is the most common condition seen by eye care practitioners.
• In the USA ~8 million have moderate to severe DED.
• Patients with moderate to severe DED have a quality of life, comparable to those with moderate to severe angina.
• DED is growing rapidly worldwide.
• CF is the most common fatal genetic disorder in the Caucasian population.
• Around 80,000 people worldwide have CF.
• CF is still under diagnosed.
• At present, CF is incurable.

• “there is no strong evidence that any topical therapy is effective for
relieving the sensation of dry mouth”.
• Excluding Kepivance (6% of cases), there are no effective treatments (RIX- Beatson Cancer Clinicians).
• Inflammation and oral infection are also common consequences of
HNC radiotherapy.
• “a broad spectrum of formulations is available as artificial tears and ocular lubricants. Most products, however, offer only
symptomatic and short-term relief”.
• Patients are susceptible to chronic inflammation and eye infections.
• Patients experience repeat unresolved infections, chronic inflammation and bacteria develop resistance to antibiotics.
• Treatments aim to treat the consequences of the disease with the exception of Kalydeco which only treats around 3-5% of patients.
• Average survival age of around 40 years.

• Regulatory
– Co-sponsored study.
– Protocol Input (clinical relevance).
– Early introduction to the ethical/regulatory process (CTEC).
– Study covered by NHS Indemnity and Insurance.
• Resource
– Access to GGCHB Phase 1 clinical trials unit (skills, cost)
– Access to GGCHB vendor relationships e.g. Robertson Centre for
Biostatistics
– Coverage of Greater Glasgow academic units e.g. Glasgow Caledonian
University.
• Research Facilities e.g.
– Preclinical ex-vivo study in RIX at the Beatson.
– Access to specialised equipment, staff and samples.

• Co-sponsored status
– protocol input: clinical v commercial aspects (low).
• Contracting
– NHS time lines are longer than commercial CROs (medium).
• Project Management
– Input required from Lamellar for internal GGCHB functions (medium).
• Access to Staff
– Clinical/academic vs Lamellar priorities (low to medium).
• Publication rights
– Commercial vs Academic interests (low).
• IP rights
– Need to be addressed - ownership and commercial licensing (Medium)

RIX Dry Mouth
• Successful 30 patient ex vivo study in patients with
Head & Neck (H&N) cancer undergoing radiotherapy.
• Presentation of results at:
– International Conference on Innovative Approaches in H&N
Oncology.
– 3rd European Society for Radiotherapy & Oncology forum.
– Multinational Association of Supportive Care in Cancer.
• Published in “Supportive Care in Cancer”.
• At CE Device audit for clinical trial authorisation.
• Clinical study in H&N cancer submitted for approval.

Dry Eye
 Fully funded PhD program with GCU covering:
• Filamentary Keratitis;
• Sjogrens Syndrome;
• Environmental Induced Dry Eye;
• Contact Lens Compatibility.
 Product at CE Device audit for market authorisation.
 Full clinical study with GCU in Dry Eye going to submission.

Cystic Fibrosis
 Lamellar funded medical PhD into form, function and frequency of lamellar bodies in
CF.
 Successful SE SMART grant of £430 to support pre-clinical CF research program.
 Clinical study with West of Scotland CF unit going to submission.